PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRV
Post# of 77
(Total Views: 180)
Posted On: 08/13/2018 6:01:43 PM
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is Named for its Attention to Preventative Health Care
- Private placement of $4.9 million in June 2018
- Five R&D programs currently underway
- Preventative health care market set to reach $200 billion by 2025
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is on a mission neatly expressed in its name and in the metaphoric maxim “an ounce of prevention is worth a pound of cure.” Yet, notwithstanding that axiom, medicinal practice and health care have been viewed, for almost a millennium, mainly as “cure,” despite always being administered with a dose of “prevention.” Now, in the 21st century, that auxiliary aspect seems to be gaining the recognition it deserves, and preventative health care has developed into a healthy market set to reach $200 billion by 2025. With a range of advanced therapeutic products in the development pipeline, including its Sol-gel delivery platform, Nature Identical™ Peptides from Caribbean blue scorpion venom that target cancer and dual gene therapies for type 2 diabetes and obesity, PreveCeutical Medical could make that market even bigger. PreveCeutical, based in Vancouver, is a health and wellness company focused on developing natural and nature identical products for the benefit of health-conscious consumers.
An update from securities research and capital markets advisory firm Crystal Equity Research provides an account of recent developments at PreveCeutical Medical (http://nnw.fm/g5KQq). The company received an infusion of capital in June 2018 from a non-brokered private placement amounting to C$6.5 million ($4.9 million), paving the way for its R&D program to advance rapidly. The company’s lead product candidate is a non-opioid analgesic based on cannabinoids that is administered through its proprietary Sol-gel system. The Sol-gel nose-to-brain drug delivery platform delivers a therapeutic compound to a targeted site at a slow, controlled rate.
Many potentially valuable drugs for treating neurological disorders are unable to reach the brain in sufficient concentration to be therapeutically valuable because of the blood brain barrier. This is a protective membrane that protects the brain from potentially harmful foreign substances. The blood brain barrier stops some 98 percent of drug molecules from entering the brain, and so intranasal delivery of therapeutic agents is one method being employed to circumvent it in a non-invasive manner.
The Sol-gel platform allows a therapeutic agent to be administered via the nostrils, where it changes rapidly to a gel upon contact with mucosal tissue. The gel, which continues to line the nasal passage for up to seven days, slowly releases the therapeutic agent over time. It was developed in conjunction with the University of Queensland in Australia. PreveCeutical’s team in Australia recently began testing alternative spray devices for use with the Sol-gel system, and a non-disclosure agreement has been signed with one company which has a successful drug approval track record and good manufacturing standards for pharmaceutical devices.
The market for controlled-release drug delivery solutions is expected to reach $90.2 billion by 2025, according to Grandview Research, boosted by demand from several demographics. There is an increasing need for alternative drug delivery methods for seniors, on the one hand, and for pediatric patients, on the other. Administering therapeutic agents through the nasal passage is one methodology that is under active consideration at present, since it offers a non-invasive and convenient method to bypass the blood-brain barrier and deliver the agents directly to the brain. Moreover, administration via the nasal channel offers the possibility of reduced dosages, lower dosage frequency, fewer adverse gastrointestinal effects, improved patient compliance, more uniform drug effect and better overall medication efficacy.
PreveCeutical aims to be a leader in preventive health sciences and, apart from the Sol-gel project, currently has four other research and development programs, including dual gene therapy for curative and prevention therapies for type 2 diabetes and obesity; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement for highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions and other mild traumatic brain injuries.
The company also sells CELLB9®, an immune system booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean blue scorpion venom.
For more information, visit the company’s website at www.PreveCeutical.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Private placement of $4.9 million in June 2018
- Five R&D programs currently underway
- Preventative health care market set to reach $200 billion by 2025
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is on a mission neatly expressed in its name and in the metaphoric maxim “an ounce of prevention is worth a pound of cure.” Yet, notwithstanding that axiom, medicinal practice and health care have been viewed, for almost a millennium, mainly as “cure,” despite always being administered with a dose of “prevention.” Now, in the 21st century, that auxiliary aspect seems to be gaining the recognition it deserves, and preventative health care has developed into a healthy market set to reach $200 billion by 2025. With a range of advanced therapeutic products in the development pipeline, including its Sol-gel delivery platform, Nature Identical™ Peptides from Caribbean blue scorpion venom that target cancer and dual gene therapies for type 2 diabetes and obesity, PreveCeutical Medical could make that market even bigger. PreveCeutical, based in Vancouver, is a health and wellness company focused on developing natural and nature identical products for the benefit of health-conscious consumers.
An update from securities research and capital markets advisory firm Crystal Equity Research provides an account of recent developments at PreveCeutical Medical (http://nnw.fm/g5KQq). The company received an infusion of capital in June 2018 from a non-brokered private placement amounting to C$6.5 million ($4.9 million), paving the way for its R&D program to advance rapidly. The company’s lead product candidate is a non-opioid analgesic based on cannabinoids that is administered through its proprietary Sol-gel system. The Sol-gel nose-to-brain drug delivery platform delivers a therapeutic compound to a targeted site at a slow, controlled rate.
Many potentially valuable drugs for treating neurological disorders are unable to reach the brain in sufficient concentration to be therapeutically valuable because of the blood brain barrier. This is a protective membrane that protects the brain from potentially harmful foreign substances. The blood brain barrier stops some 98 percent of drug molecules from entering the brain, and so intranasal delivery of therapeutic agents is one method being employed to circumvent it in a non-invasive manner.
The Sol-gel platform allows a therapeutic agent to be administered via the nostrils, where it changes rapidly to a gel upon contact with mucosal tissue. The gel, which continues to line the nasal passage for up to seven days, slowly releases the therapeutic agent over time. It was developed in conjunction with the University of Queensland in Australia. PreveCeutical’s team in Australia recently began testing alternative spray devices for use with the Sol-gel system, and a non-disclosure agreement has been signed with one company which has a successful drug approval track record and good manufacturing standards for pharmaceutical devices.
The market for controlled-release drug delivery solutions is expected to reach $90.2 billion by 2025, according to Grandview Research, boosted by demand from several demographics. There is an increasing need for alternative drug delivery methods for seniors, on the one hand, and for pediatric patients, on the other. Administering therapeutic agents through the nasal passage is one methodology that is under active consideration at present, since it offers a non-invasive and convenient method to bypass the blood-brain barrier and deliver the agents directly to the brain. Moreover, administration via the nasal channel offers the possibility of reduced dosages, lower dosage frequency, fewer adverse gastrointestinal effects, improved patient compliance, more uniform drug effect and better overall medication efficacy.
PreveCeutical aims to be a leader in preventive health sciences and, apart from the Sol-gel project, currently has four other research and development programs, including dual gene therapy for curative and prevention therapies for type 2 diabetes and obesity; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement for highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions and other mild traumatic brain injuries.
The company also sells CELLB9®, an immune system booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean blue scorpion venom.
For more information, visit the company’s website at www.PreveCeutical.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)